Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma
Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma
复制标题
DOI：
10.1097/mph.0000000000001326
复制
发表时间：
2019-04-01
影响因子：
1.2
通讯作者：
Baruchel, Sylvain
中科院分区：
文献类型：
--
作者：
Alexander, Natasha;Marrano, Paula;Baruchel, Sylvain
正在研究替代放射性标记的靶向药物，用于治疗对 I-131-间碘苄胍 (MIBG) 治疗无反应的复发性神经母细胞瘤 (NB) 儿童。 (DOTA(0)-Tyr(3))-奥曲酸靶向生长抑素受体 (SSTR)，特别是在 NB 细胞上表达的 SSTR2。我们研究了 NB 肿瘤（36 名高危 [HR]；33 名非 HR 患者）中的 SSTR2 表达，并将 SSTR2 水平与临床特征、去甲肾上腺素转运蛋白 (NET) 表达和 MIBG 亲和力相关联。使用基于染色强度和分布的数字图像分析来计算活检的 SSTR2 和 NET 免疫组织化学评分（0 至 3）。临床数据与SSTR2表达相关。 69 名患者的中位 SSTR2 评分为 1.31（0.26 至 2.55）。非 HR NB 与较高的 SSTR2 评分相关（P=0.032）。 SSTR2 表达与年龄、国际神经母细胞瘤分期系统 (INSS) 分期、MYCN 扩增和组织学无关。与 MIBG 非亲和性 NB 相比，MIBG 亲和性 NB 中观察到较高的 SSTR2 评分。 SSTR2评分与NET评分无显着相关性（r=-0.062，P=0.62）。 26 名复发或进展的患者的中位 SSTR2 评分为 1.33（0.26 至 2.55）。包括复发或进展性疾病在内的 NB 患者在诊断时表现出 SSTR2 表达，表明他们可能是放射性标记 DOTA 缀合肽成像或治疗的候选者。
Alternative radiolabeled, targeted agents are being investigated for children with relapsed neuroblastoma (NB) who do not respond to I-131-metaiodobenzylguanidine (MIBG) therapy. (DOTA(0)-Tyr(3))-octreotate targets somatostatin receptors (SSTRs), particularly SSTR2, which are expressed on NB cells. We investigated SSTR2 expression in NB tumors (36 high-risk [HR]; 33 non-HR patients) and correlated SSTR2 levels with clinical features, norepinephrine transporter (NET) expression, and MIBG avidity. SSTR2 and NET immunohistochemistry scores (0 to 3) were calculated on biopsies using digital image analysis based on staining intensity and distribution. Clinical data were correlated with SSTR2 expression. Median SSTR2 score for 69 patients was 1.31 (0.26 to 2.55). Non-HR NB was associated with a higher SSTR2 score (P=0.032). The SSTR2 expression did not correlate with age, International Neuroblastoma Staging System (INSS) stage, MYCN amplification and histology. Higher SSTR2 scores were observed in MIBG-avid versus MIBG-nonavid NB. SSTR2 score was not significantly associated with NET score (r=-0.062, P=0.62). Twenty-six patients who relapsed or progressed had a median SSTR2 score of 1.33 (0.26 to 2.55). Patients with NB including relapsed or progressive disease showed SSTR2 expression at diagnosis, suggesting they could be candidates for radiolabeled-DOTA-conjugated peptide imaging or therapy.